If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in EuropeScemblix ...

In Canada, Scemblix ® was previously approved for the treatment of adult patients with Ph+ CML-CP previously treated with two or more TKIs. Newly diagnosed patients will now have access to a treatment ...

One-on-one and group investor meetings on November 5 Stifel 2025 Healthcare Conference: Presentation on November 13 at 2:40 pm EST (NASDAQ: AAPG; HKEX: 6855) (“ Ascentage Pharma ” or the “ Company ”) ...

The metastasis suppressor 1 (Mtss1) protein acts a tumour suppressor in chronic myeloid leukaemia (CML) stem cells, reveals research published in Leukemia. Using a double transgenic mouse model of CML ...

EMA committee recommends marketing approval for Novartis’ Scemblix to treat adults with newly diagnosed CML: Basel Monday, October 20, 2025, 11:00 Hrs [IST] Novartis announced t ...

Cycle Pharmaceuticals announces the launch of PHYRAGO, its first oncology product in the US. PHYRAGO is launched in ...

When oral medicines for Chronic Myeloid Leukemia (CML) first became available, they dramatically changed what it meant to ...

Association of polypharmacy with acute care utilization in older adults receiving androgen receptor signaling inhibitors for metastatic prostate cancer. Understanding communication and healthcare ...

Federally funded science is critical to discovering new treatments for disease. Just ask Melvin Mann, who was a 37-year-old Army major when doctors diagnosed him with an aggressive and deadly blood ...

If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in EuropeScemblix i ...

If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, ...